Related Experiment Videos
Effects of GRAS substances on pharmacologic effects of drugs
Clinical Pharmacology and Therapeutics
|November 1, 1977
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Pharmacogenetics of paraoxonases: a brief review.
Naunyn-Schmiedeberg's archives of pharmacology·2003
Baculovirus-mediated expression and purification of human serum paraoxonase 1A.
Journal of lipid research·2001
Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R.
Pharmacogenetics·2001
Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals.
Drug metabolism and disposition: the biological fate of chemicals·2001
Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.
Drug metabolism and disposition: the biological fate of chemicals·2000
Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer.
Clinical pharmacology and therapeutics·2026
Exposure-Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First-Line Therapy for Locally Advanced or Metastatic Urothelial Cancer.
Clinical pharmacology and therapeutics·2026
Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma.
Clinical pharmacology and therapeutics·2026
Toward Fit-for-Purpose Data for Drug Assessment in Non-small Cell Lung Cancer: A Core Dataset.
Clinical pharmacology and therapeutics·2026
Sarcolipin is a Conformation-Dependent Regulator of the Sarcoplasmic Reticulum Calcium Pump SERCA.
The Journal of membrane biology·2026
Scopolamine ameliorates psoriasis by blocking M1 receptor-mediated IL-23 production in dendritic cells.
Journal of immunology (Baltimore, Md. : 1950)·2026
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.
Handbook of experimental pharmacology·2026
Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism?
The Journal of clinical endocrinology and metabolism·2026